RxSight, Inc. (RXST)

RxSight's stock price has been volatile over the past six months. In January 2026, RXST shares increased by 14.1% due to investor optimism following preliminary financial results and the appointment of a new CFO, despite a 30% loss in the prior four weeks. In July 2025, the stock declined by 37.84% after disappointing preliminary Q2 2025 results and lowered full-year guidance, with a significant drop in Light Delivery Device sales. In April 2025, RXST declined by 37.94% following the announcement of preliminary Q1 2025 revenue, which decreased from Q4 2024, and revised full-year guidance due to market headwinds. Overall, the stock has underperformed the S&P500 Index by -74.11% over the past year, with a six-month return of +11.1%.

RxSight anticipates overall quarterly sequential growth for its products and services, but with expected seasonality. Softer sequential growth is projected for capital equipment, particularly the Light Delivery Device (LDD), in the first quarter, while continued growth in Light Adjustable Lens (LAL) procedures is expected. Seasonality is also anticipated in the third quarter.

RxSight, Inc. is a commercial-stage medical technology company focused on providing customized vision to patients after cataract surgery. It operates in the Healthcare sector, specifically the Medical Devices or Medical Instruments industry. The company's core business is centered around its RxSight Light Adjustable Lens (LAL) system, which includes the LAL intraocular lens and the RxSight Light Delivery Device (LDD). RxSight employs a "razor and razor blade" business model, selling LDDs used to adjust and optimize LALs.

Headquartered in Aliso Viejo, California, RxSight's LAL technology is primarily used in cataract surgery within the U.S., with a network of implantation sites across North America. The company has CE marking in Europe and FDA approval for its second-generation device in the U.S. RxSight is preparing for broader global expansion, with recent regulatory approvals in South Korea and anticipated approvals in the UK.

RxSight's brand reputation has been impacted by a shift in surgeon sentiment regarding its Light Adjustable Lens (LAL) technology and multiple securities class-action lawsuits alleging misleading financial guidance and insider trading. Investors accuse the company of overstating LAL and LDD sales and downplaying a slowdown in adoption, which could erode investor confidence and negatively affect the company's brand reputation.

RxSight, Inc. has a mixed ownership structure including institutional, retail, and individual investors. Institutional investors hold approximately 27.34% to 76.77% of the company's stock. Major institutional owners include BlackRock, Inc., Millennium Management Llc, Vanguard Group Inc, D. E. Shaw & Co., Inc., and Artisan Partners Limited Partnership. Insiders own approximately 5.60% of the stock, with some directors selling shares at peak prices before negative disclosures.